Pharmacological Properties of a New Selective Antiprogestagen: Org 33628
- 1 June 1995
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 761 (1) , 192-201
- https://doi.org/10.1111/j.1749-6632.1995.tb31379.x
Abstract
Click on the article title to read more.Keywords
This publication has 7 references indexed in Scilit:
- Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroidsJournal of Clinical Endocrinology & Metabolism, 1993
- Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissuesThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell lineJournal of Clinical Endocrinology & Metabolism, 1992
- Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299.Proceedings of the National Academy of Sciences, 1992
- Treatment of breast cancer with different antiprogestins: Preclinical and clinical studiesThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- The New Aromatase Inhibitor CGS-16949A SuppressesAldosterone and Cortisol Production by Human Adrenal Cellsin vitroJournal of Clinical Endocrinology & Metabolism, 1989
- Pharmacological Profile of RU 486 in AnimalsPublished by Springer Nature ,1985